arrow
Return

Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma

delete2021-05-01
delete16
PRE
AI
A
Alexandra N. De Leo
A
Adam L. Holtzman *
M
Meng Wei Ho
C
Christopher G. Morris
M
Michael S. Rutenberg
R
Ronny L. Rotondo
J
James E. Bates
D
Daniel J. Indelicato
D
Dinesh Rao
M
Mohammad ASA Hasan
W
William M. Mendenhall
DOI:10.1016/j.radonc.2021.02.012delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Background & purpose: Dose escalation for skull-based chordoma and chondrosarcoma can put critical adjacent structures at risk, specifically the anterior optic pathway. We report the incidence of vision loss following high-dose conformal proton-based radiotherapy. Materials and methods: We reviewed patients with skull-base chordoma or chondrosarcoma treated with proton-based therapy between 2007 and 2018. We analyzed 148 patients and 283 individual eyes with functional vision at baseline who received a minimum 30GyRBE to 0.1 cm(3) of the anterior optic pathway. Eyes were classified as functionally blind if visual acuity was 20/200 or worse. Kaplan-Meier and normal tissue complication probability modeling were used to establish the relationship between radiation dose and risk of functional vision loss. Results: At last follow-up, 110 of 148 patients were alive with no evidence of disease progression. With a median follow-up of 4.1 years (range, 0.5-12.8), 5 eyes in 3 patients developed functional blindness, with 2 patients developing bilateral blindness. Median time to blindness was 15.2 months. The 5-year incidence of vision loss was 2.1% (95% CI: 0.9-4.9%). On univariate analysis, development of blindness was associated with presence of multiple medical comorbidities (p = 0.0040). While there were no events with a maximum dose < 60GyRBE delivered to the anterior optic pathway, the crude rate was 3.6% over 60GyRBE, with all events occurring between 60-65GyRBE. Conclusions: Despite the high radiotherapy dose delivered to patients with skull-base chordoma and chondrosarcoma, the rate of vision loss is low and no events occurred in those who received a maximum dose under 60GyRBE. (C) 2021 Published by Elsevier B.V.
Keywords:
Vision loss
Head and neck
Central nervous system
Proton therapy
Toxicity
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Radiotherapy and Oncology cover
Radiotherapy and Oncology
IF:
5.3
Papers:
2.1W
Citations:
2.4W

Organization

U
University of Florida
Scholars:
4.0W
Papers: 3.1W
Citations: 6.6W
State University System of Florida cover
State University System of Florida
Scholars:
12.6W
Papers: 10.8W
Citations: 130
U
university of kansas medical center
Scholars:
6.5K
Papers: 5.0K
Citations: 6
U
University of Kansas
Scholars:
1.9W
Papers: 1.7W
Citations: 8.1K
researcher View more organizations